A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

This study is testing the drug IBI363 (a new type of immunotherapy) in combination with either bevacizumab or furuitinib (both anti-angiogenic drugs that cut off blood supply to tumors) in people with advanced colorectal cancer that has stopped responding to standard treatments. **You may be eligible if...** - You are 18–75 years old with confirmed advanced colorectal cancer - Your cancer has progressed after standard therapy, or you have no standard options available - You have at least one measurable tumor on imaging - You are in good general health (ECOG 0–1) - You have adequate organ function and a life expectancy of 3 months or more - You agree to use effective contraception **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active brain metastases or seizures - You have significant heart or blood vessel disease - You have severe lung disease (interstitial pneumonia, pulmonary fibrosis, etc.) - You have severe allergies or asthma Talk to your doctor to see if this trial is right for you.